ClinicalTrials.gg
WithdrawnNCT06291415Updated Sep 16, 2025

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

A Phase 1 interventional study of HMPL-523 in Immune Thrombocytopenia, Blood Platelet Disorder and Hematologic Diseases, sponsored by Hutchmed. Withdrawn at 28 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.

Enrollment
90th of 94
0 · median 42
Started
2024
with 3 others
Phase 1
15 of 110
3 open now
Registered
92nd of 110
by date

Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 90th largest by enrollment of the 94 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 in phase 1, and was the 92nd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.

Read the detailed description

This study is a Phase 1b, open-label, multicenter, single-arm study to evaluate the safety, tolerability, and preliminary efficacy of HMPL-523 in adult subjects with primary ITP diagnosed at least 3 months prior to enrollment or randomization.

In the dose escalation stage (Part 1), subjects will receive one of 3 dose levels of HMPL-523 to determine the recommended dose of HMPL-523 for the randomized dose optimization- stage (Part 2).

At the end of Part 1, 2 dose levels will be selected to be used in the dose-optimization stage (Part 2) of the study. In Part 2 of the study, subjects will be randomized in a 1:1 ratio between the 2 dose levels to better understand the exposure/efficacy/toxicity relationship.

At the end of Part 2, the Recommended Phase 3 dose (RP3D) of HMPL-523 will be determined based on the safety, efficacy and PK data.

03

Conditions studied

  • Immune Thrombocytopenia
  • Blood Platelet Disorder
  • Hematologic Diseases
  • Purpura, Thrombocytopenic
  • Purpura
  • Blood Coagulation Disorder
  • Thrombotic Microangiopathies
  • Hemorrhagic Disorders
  • Autoimmune Diseases
  • Immune System Diseases
  • Hemorrhage
  • Pathologic Processes
  • Skin Manifestations
  • Thrombocytopenia
  • Purpura, Thrombocytopenic, Idiopathic
  • Primary Immune Thrombocytopenia
  • ITP - Immune Thrombocytopenia

Keywords

  • ITP
  • sovleplenib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects may be enrolled in this study only if they satisfy all the following criteria:

  1. Adult male or female subjects ≥18 years of age
  2. Diagnosis of ITP, with a duration of disease of at least 3 months prior to randomization or enrollment
  3. Intolerance or insufficient response or recurrence after at least 1 prior ITP treatment (excluding splenectomy)
  4. Response (defined as achieved a count ≥50 × 109/L) to at least 1 prior ITP therapy (including splenectomy)
  5. Adequate hematologic, hepatic and renal function

Exclusion criteria

Exclusion Criteria:

Subjects are not eligible for enrollment into this study if any one of the following criteria are met:

  1. Evidence of the presence of secondary causes of ITP
  2. Clinically serious hemorrhage requiring immediate adjustment of
  3. Known history of vital organ transplantation or hematopoietic stem-cell transplantation or chimeric antigen receptor T-cells (CAR-T) therapy
  4. Splenectomy within 12 weeks prior to enrollment
  5. Presence of active unless deemed cured by adequate treatment.
  6. History of serious cardiovascular disease interval (QTcF) ≥450 ms
  7. Uncontrolled hypertension
  8. Being unsuitable to participate in this study as considered by investigators
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Part 1 will consist of the following 3 dose levels: 300, 400, and 500 mg once daily (QD).

    Drug: HMPL-523

  • Experimental
    Dose optimization stage

    In part 2 subjects will be randomized in a 1:1 ratio between the 2 dose levels selected at the end of part 1.

    Drug: HMPL-523

Interventions

  • Syk inhibitor

    Also known as: sovleplenib

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of HMPL-523 in adult subjects with primary ITP

    Calculated as the number and percent incidence of participants experiencing adverse events (AE).

    Time frame: week 1 - week 24

  2. Dose Limiting Toxicities

    Defined as an adverse event AE that meets protocol defined Dose Limiting Toxicities (DLT) criteria during the DLT assessment window (first 28 days), unless clearly unrelated to ITP drugs.

    Time frame: week 1 - week 4

Secondary outcomes

  1. Cmax (maximum plasma drug concentration)

    Blood samples will be obtained from all patients to determine maximum plasma drug concentration of HMPL-523 and metabolite M

    Time frame: week 1 and week 3

  2. AUCtau (area under the concentration-time curve over a dosage interval)

    Blood samples will be obtained from all patients to determine area under the concentration time curve over periodic dosing intervals for HMPL-523 and metabolite M1

    Time frame: week 1 and week 3

  3. Tmax (time to reach maximum plasma drug concentration)

    Blood samples will be obtained from all patients to determine time to reach maximum plasma concentration of HMPL-523 and metabolite M1

    Time frame: week 1 and week 3

  4. Cmin (minimum plasma drug concentration)

    Blood samples will be obtained from all patients to determine minimum plasma concentration of HMPL-523 and metabolite M1

    Time frame: week 1 - week 20

07

Study locations

28 sites
  • Childrens Hospital of California
    Irvine, California 92868, United States
  • Georgetown University Medical Center - Georgetown Lombardi Comprehensive Cancer Center
    Georgetown, Delaware 20007, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • East Carolina University, Brody School of Medicine
    Greenville, North Carolina 27834, United States
  • Taussig Cancer Institute
    Cleveland, Ohio 44106, United States
  • Oklahoma Cancer Specialists and Research Institute
    Tulsa, Oklahoma 74146, United States
  • Texas Oncology San Antonio Medical Center
    San Antonio, Texas 78240, United States
  • University of Washington (UW) Medical Center
    Seattle, Washington 98195, United States
  • Peninsula Private Hospital
    Frankston, Victoria, Australia
  • The Perth Blood Institute (PBI) Hollywood Specialist Centre
    West Perth, Western Australia, Australia
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Canberra Hospital
    Canberra, Australia
  • Charite university
    Berlin, 10117, Germany
  • Marien Hospital Dusseldorf
    Düsseldorf, 40479, Germany
  • UMG Gottingen Hämatologie
    Göttingen, Germany
  • University Hospital of Schleswig-Holstein, Department of Haematology and Oncology
    Lübeck, Germany
  • Sykehuset Ostfold Kalnes (fosta) / Osfold Hospital Trust (MSL)
    Grålum, 1714, Norway
  • Oslo University Hospital
    Oslo, Norway
  • Hospital del Mar Barcelona
    Barcelona, 08003, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • University de Burgos
    Burgos, 09001, Spain
  • Hospital Gregorio Maranon Madrid
    Madrid, 28007, Spain
  • Clinica Universidad de Navarra
    Madrid, 28027, Spain
  • Hospital Infanta Leonor
    Madrid, 28031, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Morales Meseguer
    Murcia, 30008, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Apr 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Mar 4, 2024
StartActual
Apr 2, 2024
Primary completionEst.
Apr 2026
CompletionEst.
Nov 2026
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06291415
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Apr 2, 2024
Primary completion
Apr 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 16, 2025

Study contacts

William Schelman, MD, PhD
study director · Hutchmed

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion